(P077) Defining the Pendulum Swing From Whole-Pelvic Radiation Therapy (WPRT) Alone to Vaginal Brachytherapy (VB) in the Adjuvant Setting for Endometrial Cancer: A SEER-Based Analysis From Years 2000–2011

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

This SEER study demonstrates the pronounced increase in the utilization of VB over WPRT alone in the adjuvant setting for endometrial cancer. This observation may spark critical evaluation of US practice patterns seen from 2000 to 2011 and its potential impact on cost, new policies, and the patient’s quality of life.

Sagar C. Patel, MD, Sudershan Bhatia, MD, PhD, William Rockey, MD, PhD, Mindi Tennapel, BSMS, MBA, Wenqing Sun, MD, PhD; University of Iowa Hospitals and Clinics

PURPOSE: To examine the change in the utilization trends of radiation therapy in the adjuvant setting for endometrial cancer in a Surveillance, Epidemiology, and End Results (SEER) analysis from 2000–2011.

PATIENTS AND METHODS: We analyzed the change in utilization of whole-pelvic radiation therapy (WPRT) alone, vaginal brachytherapy (VB) alone, and WPRT + VB in all patients with endometrial cancer in the adjuvant setting, stratified by age, race, marital status, specific US registry, histology, and grade. In addition, a subset analysis of endometrial cancer patients with localized-stage uterine disease, endometrioid histology, and varying age and grade was completed to model intermediate- and high-risk groups. Percentage change (PC) and annual percentage change (APC) in treatment utilization were calculated for each radiation therapy modality. APC characterizes utilization trends over time and is comparable across scales in SEER*Stat. Utilization rates were analyzed by using SEER*Stat with a log-linear regression model.

RESULTS: In the years 2000–2011, there was a 220.1% (PC) and 11.7% (APC) increase in the utilization of VB, while there was a 33.1% (PC) and 4.1% (APC) decrease in the utilization of WPRT alone (P < .05). For each demographic and clinical variable, the most pronounced increase in the utilization of VB over WPRT alone was in individuals aged ≥ 70 years (248.4% [PC] and 12.2% [APC]), in those of Asian race (584% [PC] and 13.4% [APC]), in the SEER registry Louisiana (1,216.5% [PC] and 12.5% [APC]), in grade 3 tumors (303.3% [PC] and 12.9% [APC]), and in those with carcinosarcoma histology (1,251.5% [PC] and 32.3% [APC]). On the contrary, the most pronounced decrease in the utilization of WPRT alone was in individuals aged ≥ 70 years (41.4% [PC] and 5.2% [APC]), in those of white race (37.1% [PC] and 4.4% [APC]), in the SEER registry Louisiana (60.1% [PC] and 7.0% [APC]), in grade 2 tumors (52.2% [PC] and 6.8% [APC]), and in those with carcinosarcoma histology (56.8% [PC] and 3.3% [APC]).

CONCLUSION: This SEER study demonstrates the pronounced increase in the utilization of VB over WPRT alone in the adjuvant setting for endometrial cancer. This observation may spark critical evaluation of US practice patterns seen from 2000 to 2011 and its potential impact on cost, new policies, and the patient’s quality of life.

Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.
Next steps for research in the multiple myeloma space may include the development of novel CAR T-cell strategies and bispecific antibodies.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Related Content